Pharmaceutical CRDMO Services Market Size is valued at USD 114.8 billion in 2023 and is predicted to reach USD 266.7 billion by the year 2031 at an 11.3% CAGR during the forecast period for 2024-2031.
Pharmaceutical Contract Research, Development, and Manufacturing Organization (CRDMO) services provide a comprehensive and unified solution for drug development, encompassing research, development, and manufacturing. These services encompass the entire spectrum of activities, ranging from initial drug exploration and clinical experiments to the mass production of medications. Contract Research and Development Organizations (CRDMOs) play a crucial role in refining the entire drug development process, cutting down expenses, and enhancing productivity. As a result, they are indispensable collaborators for companies seeking to introduce novel medications to the market.
The growing population is expected to create significant healthcare opportunities in the forecast period. The increasing requirement for pharmaceutical products and the need for efficient manufacturing and development processes make CDMOs vital for managing innovation and development programs under one roof. CDMOs enable pharmaceutical companies to outsource drug development and peoduction in a timely and cost-effective manner. Additionally, increased investment in research and development by the pharmaceutical industry will drive the growth of the CDMO sector.
Competitive Landscape
Some Major Key Players In The Pharmaceutical CRDMO Services Market:
- BioDuro-Sundia
- Sai Life Sciences
- Icosagen
- WuXi Biologics
- WuXi AppTec
- Esco Aster
- Jubilant Biosys
- Syngene International
- Chemveda
- Ardena Holding
- Eurofins
- Jiangsu HUAYI Technology Co., Ltd.
- Other Market Players
Market Segmentation:
The Pharmaceutical CRDMO Service Market is segmented by type and application. By type, services include Small Molecular CRDMO, Middle Molecular CRDMO, and Large Molecular CRDMO services, each catering to different scales and complexities of drug development and manufacturing. By application, CRDMOs specialize in various therapeutic areas such as Oncology, Central Nervous System (CNS) disorders, Cardiovascular diseases, Infectious Diseases, Hematology, and Vaccine development.
Based On The Product, The Oncology Segment Accounts For A Major Contributor In the Pharmaceutical CRDMO Services Market.
The oncology category is predicted to hold a major share of the global Pharmaceutical CRDMO Services market. There is a significant and growing demand for oncology drugs globally due to increasing cancer incidence and prevalence. This drives pharmaceutical companies to focus heavily on oncology drug development and manufacturing. Oncology drugs often require specialized manufacturing processes and expertise due to their complexity, including biologics, cytotoxics, and targeted therapies. CRDMOs specializing in oncology can offer the necessary capabilities and infrastructure.
The Small Molecule CRDMO Services Segment Witnessed Rapid Growth.
The Small Molecule CRDMO Services segment commands the largest share in the Pharmaceutical CRDMO Service Market for several key reasons. Firstly, small molecule drugs constitute a substantial portion of the pharmaceutical market, encompassing generics and newly developed chemical entities, which drives the demand for outsourcing their development and production. CRDMOs specializing in small molecules typically possess well-established expertise in organic synthesis, process chemistry, and formulation development, supported by a robust infrastructure for large-scale manufacturing. This specialization enables cost-effective operations, leveraging lower labour and operational costs in regions like Asia-Pacific. Moreover, these CRDMOs offer flexibility in manufacturing schedules and faster time-to-market, which is crucial for meeting regulatory timelines and market demands. Their experience in navigating complex global regulatory frameworks ensures compliance with stringent quality standards, further reinforcing their leadership in this competitive market segment.
In The Region, The North American Pharmaceutical CRDMO Services Market Holds A Significant Revenue Share.
The North American Pharmaceutical CRDMO Services market is expected to register the highest market share. The market is estimated to get bigger due to the expansion of manufacturing units within the pharmaceutical industry. The increasing overall geriatric population in the region is expected to drive higher demand for these services from the healthcare sector. Additionally, advancements in pharmaceutical technology will boost the growth of the contract research, development & manufacturing organization market. Furthermore, the well-established healthcare infrastructure and favourable government policies aimed at improving healthcare services contribute to the market's expansion in North America. In addition, Asia Pacific is likely to grow rapidly in the global Pharmaceutical CRDMO Services market. CRDMOs in APAC are adopting advanced technologies and processes for drug development and manufacturing. This includes capabilities in biologics, generics, and speciality pharmaceuticals, driving their attractiveness to global pharmaceutical companies.
Recent Developments:
- In Aug 2022, BioDuro-Sundia and X-Chem have together introduced DNA Encoded Compound Library (DEL) technology services in China. This initiative aims to assist creative pharmaceutical businesses in efficiently identifying small molecule medications. X-Chem will utilize its robust DEL technology platform and extensive library of unique, varied lead- and drug-like small molecule compounds to assist clients in greatly expediting the identification of potential hits and broadening their scope of target options.
Pharmaceutical CRDMO Services Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 114.8 Bn |
|
Revenue Forecast In 2031 |
USD 266.7 Bn |
|
Growth Rate CAGR |
CAGR of 11.3% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type and Application. |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
BioDuro-Sundia, Sai Life Sciences, Icosagen, WuXi Biologics, WuXi AppTec, Esco Aster, Jubilant Biosys, Syngene International, Chemveda, Ardena Holding, Eurofins, Jiangsu HUAYI Technology Co., Ltd. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
